http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PE-20160527-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6ebfd716a6d868cec0fdcf2af2480107
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10311
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10034
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-183
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86
filingDate 2014-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0bbd812fe249a947105d77c7ca03183
publicationDate 2016-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber PE-20160527-A1
titleOfInvention IMPROVED ADENOVIRUS FORMULATIONS
abstract The present invention provides adenovirus pharmaceutical formulations, in particular liquid pharmaceutical formulations comprising adenovirus. These formulations comprise: a recombinant adenovirus, a citrate buffer, hydroxypropyl-beta-cyclodextrin (HBCD), a salt and a non-ionic detergent, where this formulation has a pH ranging between 5.5 and 6.5. These formulations have applications in gene therapy and / or vaccine.
priorityDate 2013-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14049689
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426208976

Total number of triples: 37.